| ²é¿´: 1199 | »Ø¸´: 4 | ||||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||||
pawpawer1984гæ (СÓÐÃûÆø)
|
[ÇóÖú]
systemic exposure Ôõô·ÒëÄØ£¿Ò©Ñ§Ïà¹ØµÄ
|
|||
| Coadministered thalidomide also significantly increased the systemic exposure of CPT-11 but decreased that of SN-38 (7-ethyl-10-hydroxycampothecin). |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¾«Æ··Ò뼯½õ |
» ²ÂÄãϲ»¶
²ÄÁÏÇóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó×Ü·Ö298·Ö£¬Ç°Èý¿Æ223·Ö
ÒѾÓÐ5È˻ظ´
085600 286·Ö ²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
086502»¯Ñ§¹¤³Ì342Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏÇóµ÷¼ÁÒ»Ö¾Ô¸¹þ¹¤´ó324
ÒѾÓÐ7È˻ظ´
328Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
340Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸Äϲý´óѧ324Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Çóµ÷¼ÁÍÆ¼ö ²ÄÁÏ 304
ÒѾÓÐ15È˻ظ´
291Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
331»·¾³¿ÆÑ§Ó빤³ÌÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´

805911645
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 185
- Ìû×Ó: 47
- ÔÚÏß: 18.4Сʱ
- ³æºÅ: 1073309
- ×¢²á: 2010-08-12
- רҵ: »¯Ñ§·´Ó¦¹¤³Ì
2Â¥2012-04-09 23:02:32
pawpawer1984
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1998.8
- É¢½ð: 5
- Ìû×Ó: 55
- ÔÚÏß: 10.5Сʱ
- ³æºÅ: 1550346
- ×¢²á: 2011-12-24
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí

3Â¥2012-04-09 23:19:17
ÓÖ¼ûÌìÏÂ
½ð³æ (СÓÐÃûÆø)
- ·ÒëEPI: 1
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1367.3
- ºì»¨: 18
- Ìû×Ó: 202
- ÔÚÏß: 41.1Сʱ
- ³æºÅ: 1363848
- ×¢²á: 2011-08-09
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2012-04-10 12:05:48
°®ÓëÓêÏÂ: , Welcome ! 2012-04-10 12:06:38
sltmac: ½ð±Ò+5, ·ÒëEPI+1 2012-04-24 10:25:17
°®ÓëÓêÏÂ: ½ð±Ò+1 2012-04-10 12:05:48
°®ÓëÓêÏÂ: , Welcome ! 2012-04-10 12:06:38
sltmac: ½ð±Ò+5, ·ÒëEPI+1 2012-04-24 10:25:17
| ¿ÉÒÔ½âÊÍÎªÈ«Ãæ½Ó´¥¡¢ÏµÍ³ÐÔ±©Â¶»òÈ«ÉíÐÔ±©Â¶£¬ÈçAerosolized medications maximize clinical benefit by targeting the airways and minimize side effects by reducing (though not eliminating) systemic exposure.Îí»¯Æ÷¸øÒ©Í¨¹ýÆøµÀ¸øÒ©´ïµ½×î´óµÄÁÙ´²ÀûÒæºÍͨ¹ý¼õµÍ£¨¶ø²»ÊÇÏû³ý£©È«ÉíÐÔ±©Â¶×îСµÄ¸±·´Ó¦¡£ |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
4Â¥2012-04-10 11:50:43
pawpawer1984
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1998.8
- É¢½ð: 5
- Ìû×Ó: 55
- ÔÚÏß: 10.5Сʱ
- ³æºÅ: 1550346
- ×¢²á: 2011-12-24
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí

5Â¥2012-04-11 11:35:24














»Ø¸´´ËÂ¥
pawpawer1984
6